These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7685840)

  • 1. [Determination of tumor marker doubling time in the patients with prostate cancer relapsed from endocrine therapy].
    Akimoto S; Masai M; Kitagawa N; Nakamura T; Shimazaki J
    Nihon Hinyokika Gakkai Zasshi; 1993 Mar; 84(3):450-6. PubMed ID: 7685840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
    Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
    Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes in prostatic acid phosphatase, gamma-seminoprotein and prostate specific antigen after endocrine therapy for stage D2 prostate cancer].
    Akimoto S; Akakura K; Masai M; Isaka S; Shimazaki J
    Hinyokika Kiyo; 1990 Jul; 36(7):783-91. PubMed ID: 1700588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time.
    Akimoto S; Masai M; Akakura K; Shimazaki J
    Eur Urol; 1995; 27(3):207-12. PubMed ID: 7541360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Studies on relationship between histology, tumor markers (prostatic acid phosphatase.prostate specific antigen.gamma-seminoprotein.leu-7) and clinical course in prostate cancer].
    Tanahashi T; Namba K; Murao T
    Nihon Hinyokika Gakkai Zasshi; 1990 May; 81(5):680-5. PubMed ID: 1695956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical studies on tumor markers for monitoring prostate cancer patients; the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and gamma-seminoprotein].
    Shinoda I
    Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2627-39. PubMed ID: 1703555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple marker evaluation in prostatic cancer with prostatic acid phosphatase, gamma-seminoprotein and prostate-specific antigen.
    Fuse H; Umeda K; Mizuno I; Katayama T
    Int Urol Nephrol; 1991; 23(5):455-63. PubMed ID: 1718922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PSA doubling time in prostate cancer relapsed after endocrine therapy].
    Nakata S; Takahashi H; Takezawa Y; Kobayashi M; Matumoto K; Kosaku N; Kawashima K
    Nihon Hinyokika Gakkai Zasshi; 2000; 91(7-8):584-8. PubMed ID: 10965743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue markers in the diagnosis and prognosis of prostatic carcinoma.
    de Matteis A
    Eur Urol; 1992; 21 Suppl 1():66-70. PubMed ID: 1385134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study of tumor markers in prostatic cancer].
    Ishihara Y; Fukagai T; Ohta K; Hiromoto Y; Hiramori M; Torii T; Higaki Y; Imamura K
    Hinyokika Kiyo; 1990 Apr; 36(4):425-31. PubMed ID: 1696063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PSA-related parameters in prostate cancer relapsed after endocrine therapy].
    Nakata S; Takahashi H; Takezawa Y; Kobayashi M; Matumoto K; Kosaku N; Kawashima K
    Nihon Hinyokika Gakkai Zasshi; 2002 Sep; 93(6):686-93. PubMed ID: 12385093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The significance of serum prostate-specific antigen, gamma-seminoprotein and prostatic acid phosphatase as prostate cancer markers].
    Yamaguchi K; Tanaka M; Kitagawa N; Kotake T; Yanagi S; Ito H
    Hinyokika Kiyo; 1989 Jun; 35(6):987-91. PubMed ID: 2478006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Discrepancy between the serum levels of gamma seminoprotein and prostate-specific antigen in patients with prostatic neoplasms. Both true or either untrue].
    Fujino A; Mukai N; Kawakami T; Yokoyama E; Mashimo S; Endo T; Ishibashi A; Koshiba K; Aoki Y; Itoh H
    Nihon Hinyokika Gakkai Zasshi; 1991 Apr; 82(4):541-50. PubMed ID: 1711133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
    Akimoto S; Akakura K; Shimazaki J
    Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical studies on tumor markers in prostate cancer; the evaluation of PA (prostate specific antigen) and comparison with PAP and gamma-Sm].
    Shinoda I; Kuriyama M; Takeuchi T; Takahashi Y; Ban Y; Kawada Y
    Nihon Hinyokika Gakkai Zasshi; 1988 Apr; 79(4):635-42. PubMed ID: 2465430
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein].
    Yoshiki T; Okada K; Oishi K; Yoshida O
    Hinyokika Kiyo; 1987 Dec; 33(12):2044-9. PubMed ID: 2452559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in hemodialysis patients.
    Sasagawa I; Nakada T; Hashimoto T; Ishigooka M; Kubota Y; Hirano K; Hirano J; Suzuki Y
    Urol Int; 1992; 48(2):181-3. PubMed ID: 1374977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative evaluation of PAP and gamma-Sm as the tumor markers of prostatic cancer.
    Ito H; Nakagami Y; Lin TT; Ikeda K; Oka F
    Nihon Ika Daigaku Zasshi; 1988 Apr; 55(2):217-8. PubMed ID: 3392172
    [No Abstract]   [Full Text] [Related]  

  • 19. Gamma-seminoprotein--a new tumour marker in prostatic cancer? Results of a pilot study.
    Maier U; Simak R
    Br J Urol; 1990 May; 65(5):509-12. PubMed ID: 1693867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between reactivation and tumor markers in prostatic cancer].
    Fuse H; Umeda K; Kazama T; Sakamoto M; Sakai T; Fujishiro Y; Mizuno I; Katayama T
    Hinyokika Kiyo; 1991 Jan; 37(1):39-43. PubMed ID: 1707217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.